Trial Profile

A multi-national clinical trial assessing OM336 in patients with active autoimmune cytopenias, including relapsed/refractory autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CM 336 (Primary)
Indications Autoimmune haemolytic anaemia; Cytopenia; Idiopathic thrombocytopenic purpura
Focus Therapeutic Use

19 Jun 2025 New trial record
12 Jun 2025 According to Ouro Medicines media release, company expects to initiate the study in the second half of this year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com